PRX: Summary for PHARMACUTICAL CO - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Tuesday, November 24, 2009, 4:33am EST - Canadian Markets open in 4 hours and 57 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Par Pharmaceutical Companies Inc. (PRX)

On Nov 23: 23.99 USD 0.00 (0.00%)

MORE ON PRX

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

PHARMACUTICAL CO (NYSE:PRX) Delayed quote data

Last Trade:	23.99 USD
Trade Time:	Nov 23
Change:	0.00 (0.00%)
Prev Close:	23.99
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	20.25

Day's Range:	N/A - N/A
52wk Range:	8.57 - 24.23
Volume:	0
Avg Vol (3m):	505,186
Market Cap:	835.31M
P/E (ttm):	16.53
EPS (ttm):	1.45
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Free Annual Reports

Add PRX to Portfolio

Download Data

HEADLINES

•	Drugmaker Par Shapes A Base But Needs Time
	Investor's Business Daily (Fri, Nov 20)

•	Par Pharmaceutical to Host Analyst Day on December 3rd
	PRNewswire (Mon, Nov 16)

•	Par Pharma gets FDA approval for generic Ultram ER
	AP (Mon, Nov 16)

•	UPDATE - Par Pharma gets FDA nod for generic version of Ultram
	at Reuters (Mon, Nov 16)

•	Par Pharmaceutical Receives Final Approval to Market Generic Ultram(R) ER Par to Begin Shipping Tramadol ER Immediately
	PRNewswire (Mon, Nov 16)

•	PAR PHARMACEUTICAL COMPANIES, INC. Financials
	EDGAR Online Financials (Fri, Nov 13)

•	[$$] Biotech Stock Mailbag: Cardium Therapeutics
	at RealMoney by TheStreet.com (Fri, Nov 13)

•	New Star Analyst Rankings for PHARMACUTICAL CO
	StarMine (Tue, Nov 10)

•	Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,
	PRNewswire (Mon, Nov 9)

•	Par 3Q profit surges on product sales
	AP (Fri, Nov 6)

More Headlines for PRX...

ANALYST

EPS Est (next year) (Dec-07) :	1.53
EPS Est (in 2 years) (Dec-08) :	0.78
Avg Rec (current)*:	3.3
PEG Ratio:	1.05

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Par Pharmaceutical Companies, Inc. develops, manufactures, and markets generic drugs and branded pharmaceuticals for specialty markets in the United States.

Full Company Profile

Add to Portfolio

Email to a Friend

•